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Polybrominated diphenyl ethers (PBDEs) are 
used in large quantities worldwide as a flame 
retardant additive in plastic materials, paints, 
textile fabrics, and so forth (Alaee et al. 2003; 
Darnerud et al. 2001; de Wit 2002; Sjödin 
et al. 2003). Because of their leachability from 
various materials and their persistence, PBDEs 
have been identified in various environmental 
sectors, including sediment and fish from riv-
ers (Sellström et al. 1998), indoor air (Saito 
et al. 2007; Wilford et al. 2004), and house 
dust (Stapleton et al. 2005). Moreover, PBDEs 
have been identified in human tissue samples, 
such as blood and breast milk, because of their 
bio  accumulative nature (Mazdai et al. 2003; 
Schecter et al. 2003). Recently, great con-
cern has arisen about the possible impact on 
health of PBDE exposure because studies have 
revealed rising PBDE levels in the tissue from 
humans and wildlife (Hites 2004; Law et al. 
2003). Reports have indicated that the PBDE 
congeners most commonly found in human 
samples are 2,2´,4,4´-tetra  bromo  diphenyl 
ether (BDE-47), 2,2´,4,4´,5-penta  bromo-
diphenyl ether (BDE-99), 2,2´,4,4´,6-penta-
bromo  diphenyl ether (BDE-100), and 
2,2´,4,4´,5,5´-hexa  bromo  diphenyl ether 
(BDE-153), with BDE-47, in particular, being 
one of the predominant congeners found in 
humans (Hites 2004; Mazdai et al. 2003). In 
addition, more recent studies have shown that 
hydroxylated PBDEs (HO-PBDEs) and meth-
oxylated PBDEs (MeO-PBDEs) are formed as 
metabolites from parent PBDE congeners by 
oxidizing enzymes, such as cytochrome P450 
(CYP), and are also present in the plasma 
of wild animals (Verreault et al. 2005) and 
humans (Athanasiadou et al. 2008; Qui et al. 
2009) and in human breast milk (Lacorte and 
Ikonomou 2009).
Nuclear hormone receptors are ligand-
dependent transcription factors that regulate 
a variety of important physio  logic processes 
(McKenna et al. 1999). Several studies have 
reported that nuclear hormone receptors such 
as estrogen receptor (ER) and androgen recep-
tor (AR) inter  act with xeno  biotic chemicals, 
for example, persistent pesticides and polychlo-
rinated biphenyls (PCBs) (Bonefeld-Jørgensen 
et al. 2001; Kelce et al. 1995; Kojima et al. 
2003; Sohoni and Sumpter 1998; Vinggaard 
et al. 1999). This implies that these chemicals 
may disrupt the endocrine system via a variety 
of nuclear hormone receptors, and PBDEs may 
display toxicity similar to that of PCBs because 
of their structural resemblance. To date, 
in vitro and in vivo studies have reported that 
several PBDE congeners possess estrogenic and 
anti  estrogenic, and/or anti  androgenic activity 
(Hamers et al. 2006; Meerts et al. 2001; Stoker 
et al. 2005). However, although estrogenic 
responses are mediated via two subtypes of 
ERα and ERβ, which differ in their ligand 
binding ability and transactivation properties 
(Kuiper et al. 1997; McInerney et al. 1998), 
the estrogenicity of PBDEs has been evaluated 
on the basis of their effects via ERα, but not 
via ERβ. In addition, little work has been done 
on the agonistic and antagonistic activity of 
PBDEs against glucocorticoid receptor (GR) 
and thyroid hormone receptors (TRs) other 
than ERs and AR, and the nuclear hormone 
receptor activity of HO- and MeO-PBDEs 
is not fully understood. Therefore, further 
study regarding endocrine-disrupting effects of 
PBDEs, including HO and MeO-PBDEs, is 
required for assessing potential health risks.
Transactivation assays such as reporter 
gene assays have an advantage in detecting 
agonistic and antagonistic activity of various 
chemicals against nuclear hormone receptors. 
Using Chinese hamster ovary (CHO-K1) cells, 
we previously developed novel reporter gene 
assays that were highly sensitive and specific to 
chemicals and provided evidence that a variety 
of pesticides and plastisizers, such as phthalates, 
have both agonistic and antagonistic activi-
ties against ERα, ERβ, and AR (Kojima et al. 
2003, 2004; Takeuchi et al. 2005). Our recent 
study (Takeuchi et al. 2009) provided com-
parative data on GR and TRα1/β1 activity in 
addition to ERα/β and AR activities for vari-
ous phyto  chemicals in same the assay systems 
using CHO-K1 cells. In the present study, to 
elucidate the endocrine-disrupting property of 
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Ba c k g r o u n d: An increasing number of studies are reporting the existence of polybrominated 
diphenyl ethers (PBDEs) and their hydroxylated (HO) and methoxylated (MeO) metabolites in the 
environment and in tissues from wildlife and humans. 
oB j e c t i v e: Our aim was to characterize and compare the agonistic and antagonistic activities of 
principle PBDE congeners and their HO and MeO metabolites against human nuclear hormone 
receptors. 
Me t h o d s : We tested the hormone receptor activities of estrogen receptor α (ERα), ERβ, andro-
gen receptor (AR), glucocorticoid receptor (GR), thyroid hormone receptor α1 (TRα1), and TRβ1 
against PBDE congeners BDEs 15, 28, 47, 85, 99, 100, 153, and 209, four para-HO-PBDEs, and 
four para-MeO-PBDEs by highly sensitive reporter gene assays using Chinese hamster ovary cells. 
re s u l t s: Of the 16 compounds tested, 6 and 2 showed agonistic activities in the ERα and ERβ 
assays, respectively, and 6 and 6 showed antagonistic activities in these assays. 4´-HO-BDE-17 
showed the most potent estrogenic activity via ERα/β, and 4´-HO-BDE-49 showed the most 
potent anti  estrogenic activity via ERα/β. In the AR assay, 13 compounds showed antagonistic activ-
ity, with 4´-HO-BDE-17 in particular inhibiting AR-mediated transcriptional activity at low con-
centrations in the order of 10–8 M. In the GR assay, seven compounds, including two HO-PBDEs 
and two MeO-PBDEs, showed weak antagonistic activity. In the TRα1 and TRβ1 assays, only 
4-HO-BDE-90 showed weak antagonistic activity. 
co n c l u s i o n s: Taken together, these results suggest that PBDEs and their metabolites might have 
multiple endocrine-disrupting effects via nuclear hormone receptors, and para-HO-PBDEs, in 
particular, possess more potent receptor activities compared with those of the parent PBDEs and 
corresponding para-MeO-PBDEs.
key w o r d s : androgen receptor, brominated diphenyl ether, Chinese hamster ovary cells, estrogen 
receptor, glucocorticoid receptor, reporter gene assay, thyroid hormone receptor. Environ Health 
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PBDEs and their HO and MeO metabolites, 
we characterized the agonistic and antagonistic 
activity of principle PBDE congeners together 
with para-HO- and para-MeO-PBDEs against 
six hormone nuclear receptors: ERα/β, AR, 
GR, and TRα1/β1. We used BDEs 15, 28, 47, 
85, 99, 100, 153, and 209 as principle PBDEs, 
and four para-HO-PBDEs identified in human 
blood (Athanasiadou et al. 2008) and/or in 
serum from rats and mice administered PBDE 
congeners such as BDEs 47, 99, 100, and 209 
(Malmberg et al. 2005; Qui et al. 2007). The 
four para-MeO-PBDEs used in this study were 
selected because of their structural correspon-
dence to the four para-HO-PBDEs, because 
these compounds are formed through methyla-
tion of HO-PBDEs, probably by a catechol-
O-methyltransferase. Consequently, we found 
that several of the 16 tested PBDEs and metab-
olites have ERα and ERβ agonistic activity, 
and ERα, ERβ, AR, GR, TRα1, and TRβ1 
antagonistic activity. In this article, we provide 
the first evidence that parent PBDE congeners 
and para-HO- and para-MeO-PBDEs have 
multiple effects on transcriptional activity via 
nuclear hormone receptors, and that they have 
the potential to affect both the endocrine sys-
tem and reproduction in whole organisms.
Materials and Methods
Chemicals, biochemicals, and cells. We pur-
chased 17β-estradiol (E2; > 97% pure), 
5α-dihydrotestosterone (DHT; 95% pure), 
hydrocortisone (HC; > 98% pure), tamoxi-
fen citrate (TAM, 98% pure), and hydroxy-
flutamide (HF; > 99% pure) from Wako Pure 
Chemical Industries, Ltd. (Osaka, Japan). 
3,3´,5-Triiodo-l-thyronine (T3; 99% pure), 
tetrabrominated bisphenol A (TBBPA; 99% 
pure), and mifepristone (RU-486; 98% 
pure) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA).
The structures of the PBDE congeners and 
para-HO- and para-MeO-PBDEs tested in this 
study are shown in Figure 1. The PBDE con-
geners 4,4´-dibromodiphenyl ether (BDE-15), 
2,4,4´-tribromo  diphenyl ether (BDE-28), 
BDE-100, and BDE-153 were purchased 
from AccuStandard, Inc. (New Haven, CT, 
USA). We obtained deca  bromo  diphenyl ether 
(BDE-209) from Wako. We synthesized 
BDE-47 according to the method of Teclechiel 
et al. (2009), and 2,2´,3,4,4´-pentabromo-
diphenyl ether (BDE-85) and BDE-99 fol-
lowing the method of Orn et al. (1996). 
The PBDE metabo  lites 4´-hydroxy-2,2´,4-
tribromo  diphenyl ether (4´-HO-BDE-17), 
4´-methoxy-2,2´,4-tribromodiphenyl ether 
(4´-MeO-BDE-17), 4-hydroxy-2,2´,3,4´-
tetrabromo  diphenyl ether (4-HO-BDE-42), 
4-methoxy-2,2´,3,4´-tetra  bromo  diphenyl ether 
(4-MeO-BDE-42), 4´-hydroxy-2,2´,4,5´-
tetra  bromodiphenyl ether (4´-HO-BDE-49), 
4´-methoxy-2,2´,4,5´-tetrabromodiphenyl ether 
(4´-MeO-BDE-49), 4-hydroxy-2,2´,3,4´,5-
pentabromodiphenyl ether (4-HO-BDE-90), 
and 4-methoxy-2,2´,3,4´,5-penta  bromo-
diphenyl ether (4-MeO-BDE-90) were synthe-
sized according to the method of Marsh et al. 
(2003). The purities of these synthesized com-
pounds were > 98%. We used DMSO (Wako) 
as a vehicle, and all compounds were dissolved 
in DMSO at a concentration of 10–2 M.
We obtained Dulbecco’s modified Eagle 
medium (DMEM) plus Ham’s F-12 nutrient 
mixture and a penicillin-streptomycin solution 
(antibiotics) from GIBCO-BRL (Rockville, 
MD, USA); Chinese hamster ovary (CHO-K1) 
cells from Dainippon Pharmaceutical Co. 
Ltd. (Osaka, Japan); fetal bovine serum (FBS) 
and charcoal-dextran–treated FBS (CD-FBS) 
from Hyclone (Logan, UT, USA); and bovine 
serum albumin and 4-methylumbelliferyl-
β-d-galactoside from Sigma-Aldrich. We 
maintained CHO-K1 cells in DMEM/F-12 
supplemented with 5% FBS and antibiotics. 
All compounds were diluted to the desired con-
centration in an appropriate medium immedi-
ately before use. The final solvent concentration 
in the culture medium did not exceed 0.1%, 
and this concentration did not affect cell yields.
Plasmids. We prepared the expression plas-
mids pcDNAERα, pcDNAERβ, pZeoSV2AR, 
pSG5-GR, pZeo-TRα1, and pZeo-TRβ1 
encoding full-length receptor proteins and the 
reporter plasmids pGL3-tkERE, pIND-ARE, 
pGRE-tk-Luc, and pIND-TREpal as previously 
described (Kitamura et al. 2005b; Kojima et al. 
2003, 2004; Yamamoto et al. 2000). We pur-
chased the internal control plasmid, pCMVβ-
Gal, from Clontech (Palo Alto, CA, USA).
Transfection of plasmids to cells and 
luciferase activity assay. We plated the 
host CHO-K1 cells in 96-well microtiter 
plates (Nalge, Nunc, Denmark) at a den-
sity of 8,400 cells per well in phenol red-free 
DMEM/F-12 containing 5% CD-FBS (com-
plete medium) 1 day before transfection. For 
detection of human ERα (hERα) or hERβ 
activity, cells were transfected with 0.63 ng 
pcDNAERα or with 0.63 ng pcDNAERβ, 
50 ng pGL3-tkERE, and 5 ng pCMVβ-Gal per 
well using FuGENE 6 Transfection Reagent 
(Roche Diagnostics Corp., Indianapolis, IN, 
USA). For detection of hAR activity, cells were 
transfected with 2.5 ng pZeoSV2AR, 50 ng 
pIND-ARE, and 5 ng pCMVβ-Gal per well 
using FuGENE 6 Transfection Reagent. For 
detection of hGR activity, we transfected 
cells with 1.25 ng pSG5-GR, 50 ng pGRE-
tk-Luc, and 5 ng pCMVβ-Gal per well using 
FuGENE 6 Transfection Reagent. For detec-
tion of hTRα1 or hTRβ1 activity, cells were 
transfected with 1.25 ng pZeo-TRα1 or with 
1.25 ng pZeo-TRβ1, 50 ng pIND-TRE-
pal, and 5 ng pCMVβ-Gal per well using 
FuGENE 6 Transfection Reagent. After a 3-hr 
transfection period, cells were dosed with vari-
ous concentrations of the test compounds or 
with 0.1% DMSO (vehicle control) in com-
plete medium. To avoid any cyto  toxic effects 
associated with the test compounds, we per-
formed assays for test compounds at concen-
trations of < 1 × 10–5 M. For the meas  ure  ment 
of the antagonistic activities via hERα, hERβ, 
hAR, hGR, hTRα1, and hTRβ1, the test com-
pound was added to the cell cultures together 
with endogenous hormones of 1 × 10–11 M 
Figure 1. Chemical structures of the PBDEs and their HO and MeO metabolites used in the present study.
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E2, 1 × 10–10 M E2, 1 × 10–10 M DHT, 3 × 
10–8 M HC, 1 × 10–8 M T3, and 1 × 10–8 M 
T3, respectively. After an incubation period 
of 24 hr, cells were rinsed with phosphate-
buffered saline (pH 7.4) and lysed with passive 
lysis buffer (50 µL/well; Promega, Madison, 
WI, USA).
We measured firefly luciferase activity 
with a MiniLumat LB 9506 luminometer 
(Berthold, Wildbad, Germany) in one reaction 
tube with a 5-µL aliquot of the cell lysate using 
the Luciferase Assay System (Promega) accord-
ing to the manufacturer’s instructions. The 
luciferase activity was normalized against the 
β-galactosidase activity for each treatment. 
Results are expressed as mean ± SD from at 
least three independent experiments performed 
in triplicate.
β-Galactosidase activity assay. We meas-
ured β-galactosidase activity by a fluorescence 
method as described previously (Takeuchi 
et al. 2005, 2006).
Evaluation of agonistic and antagonistic 
activities. To estimate the potency of the recep-
tor agonistic activity of the tested compounds, 
we represented the luminescence intensity of 
the assay in a dose–response curve. We obtained 
the concentration of the compound equal to 
20% of the maximal response of E2, DHT, 
HC, or T3 from the dose–response curve of the 
Figure 2. Dose–response curves for E2 (A), DHT (B), HC (C), and T3 (D) obtained from the ERα/β, AR, GR, and TRα1/β1 transactivation assays, respectively, of CHO 
cells transiently transfected with an expression plasmid for hERα/β, hAR, hGR, and hTRα1/β1 as well as a reporter-responsive firefly luciferase plasmid and a 
constitutively active β-galactosidase expression plasmid. See “Methods and Methods” for details. Values represent the mean ± SD of three independent experi-
ments and are presented as the mean n-fold induction over the vehicle control. 
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luminescence intensity and expressed it as 20% 
relative effective concentration (REC20). The 
results for the receptor antagonistic activities 
of the compound are expressed as 20% relative 
inhibitory concentration (RIC20); that is, the 
concentration of the test compounds show-
ing 20% inhibition of the activities induced by 
endogenous hormones. When the agonistic or 
antagonistic activity of the test compound was 
higher than the REC20 or RIC20 value within 
the concentration tested (~ 1 × 10–5 M), we 
judged the PBDEs and their metabolites to be 
positive for agonistic or antagonistic activity 
against that nuclear hormone receptor.
Statistical analysis. We used an analysis of 
variance (ANOVA) followed by Bonferroni 
correction to evaluate the differences in tran-
scriptional levels between the control group and 
each of the chemical groups in the ERα, ERβ, 
GR, and TRα/β antagonist assays. The level of 
significance was p < 0.05. Data are presented as 
mean ± SD of three triplicate experiments.
Results
Agonistic and antagonistic activities of 
the PBDEs and their metabolites via ERα. 
Figure 2A shows the dose–response curve of 
E2 from the ERα assay. From the dose–re-
sponse curve, we estimated the REC20 value 
of E2 for ERα to be 2.5 × 10–12 M. As shown 
in Figure 3A, we found that 6 of the 16 com-
pounds tested induced estrogenic activity 
greater than the 20% of the maximum activity 
of E2 in the ERα assay. The REC20 values of 
the compounds with ERα agonistic activity 
are described in Table 1. The relative poten-
cies of their ERα agonistic activities descended 
in the following order: 4´-HO-BDE-17 
>>  4´-MeO-BDE-17,  4-HO-BDE-42 
> BDE-100 > BDE-47 > BDE-28. The estro-
genic activity via ERα of 4´-HO-BDE-17 was 
about 100,000-fold lower than that of E2.
In addition, we found that 6 of the 
16 compounds tested (BDE-99, BDE-153, 
4´-HO-BDE-17, 4´-HO-BDE-49, 4´-MeO-
BDE-49, and 4-MeO-BDE-90) had an inhibi-
tory effect on the estrogenic activity induced by 
1 × 10–11 M of E2 in the ERα assay. Figure 3B 
shows the dose response of these compounds 
and TAM, a known ER antagonist, on ERα-
mediated transcriptional activity induced by 
E2. The order of relative potencies for ERα 
antagonistic activity was 4´-HO-BDE-49, 
4-MeO-BDE-90 > BDE-153 > 4´-MeO-
BDE-49 > BDE-99 > 4´-HO-BDE-17. From 
comparisons of their RIC20 values, we esti-
mated their anti  estrogenic activity via ERα to 
be approximately 500-fold lower than that of 
TAM (Table 1). These results also indicate that 
4´-HO-BDE-17 possesses both ERα agonistic 
and antagonistic activities.
Agonistic and antagonistic activities of 
the PBDEs and their metabolites via ERβ. 
Figure 2A shows the dose–response curve of E2 
from the ERβ assay. From the dose–response 
curve, we estimated the REC20 value of E2 
for ERβ to be 5.3 × 10–12 M. As shown in 
Figure 4A, we found that of the 16 compounds 
tested, only 4´-HO-BDE-17 and 4-HO-
BDE-42 induced estrogenic activity greater the 
20% of the maximum activity of E2 in the ERβ 
assay. The REC20 values of 4´-HO-BDE-17 
and 4-HO-BDE-42 were 2.1 × 10–7 M and 3.6 
× 10– M (Table 1), and their estrogenic activity 
via ERβ was about 40,000- and 680,000-fold 
lower than that of E2, respectively.
In addition, we found that 6 of the 
16 compounds tested had an inhibitory effect 
on the estrogenic activity induced by 1 × 
10–10 M of E2 in the ERβ assay. Figure 4B 
shows the dose responses of these six com-
pounds and TAM on ERβ-mediated tran-
scriptional activity induced by E2. The order 
of relative potencies for ERβ antagonistic 
activity was 4´-HO-BDE-49 > BDE-100, 
BDE-153 > 4´-MeO-BDE-49 > 4-MeO-
BDE-90 > BDE-99. From comparisons of 
RIC20, we estimated their anti  estrogenic activ-
ity via ERβ to be between about 500- and 
1,200-fold lower than that of TAM (Table 1).
Agonistic and antagonistic activities of 
the PBDEs and their metabolites via AR. 
Figure 2B shows the dose–response curve 
for DHT obtained from the AR assay. 
Although we examined the androgenicity of 
the 16 compounds in this assay, none of the 
compounds tested showed any AR agonis-
tic activity (data not shown). However, we 
found that 12 of the 16 compounds inhibited 
the agonistic activity induced by 1 × 10–10 M 
DHT. Figure 5 shows the dose responses 
of the antagonistic activity via hAR for the 
16 compounds and HF, a known AR antago-
nist. The order of relative potencies for AR 
antagonistic activity was 4´-HO-BDE-17 
> BDE-100 > 4-HO-BDE-42, BDE-47 
> BDE-85 > 4´-HO-BDE-49 > BDE-28 
> 4´-MeO-BDE-17, BDE-99 > 4´-MeO-
BDE-49, 4-MeO-BDE-42, 4-MeO-BDE-90. 
From a comparison of RIC20 values, the anti-
androgenic activities of 4´-HO-BDE-17 and 
BDE-100 were about 5- and 10-fold lower 
than that of HF (1.8 × 10–8 M), respectively 
(Table 1).
Table 1. Comparison of agonistic and antagonistic activities of PBDEs and their HO and MeO metabolites against ERα, ERβ, AR, GR, TRα1, and TRβ1.
  Agonistic activity: REC20
a (M)  Antagonistic activity: RIC20
b (M)
Compounds  ERα  ERβ  ERα  ERβ  AR  GR  TRα1  TRβ1
E2  2.5 × 10–12  5.3 × 10–12  —  —  —  —  —  —
TAM  —  —  6.0 × 10–9  7.0 × 10–9  —  —  —  —
HF  —  —  —  —  1.8 × 10–8  —  —  —
RU-486  —  —  —  —  —  5.7 × 10–9  —  —
TBBPA  —  —  —  —  —  —  4.1 × 10–6  9.6 × 10–6
BDE-15  NE   NE  NE  NE  NE  NE  NE  NE
BDE-28  6.7 × 10–6  NE  NE  NE  1.3 × 10–6  NE  NE  NE
BDE-47  5.0 × 10–6  NE  NE  NE  8.1 × 10–7  NE  NE  NE
BDE-85  NE  NE  NE  NE  1.1 × 10–6  7.0 × 10–6  NE  NE
BDE-99  NE  NE  5.7 × 10–6  9.2 × 10–6  1.4 × 10–6  7.7 × 10–6  NE  NE
BDE-100  4.0 × 10–6  NE  NE  4.3 × 10–6  2.1 × 10–7  8.5 × 10–6  NE  NE
BDE-153  NE  NE  3.3 × 10–6  4.4 × 10–6  NE  NE  NE  NE
BDE-209  NE  NE  NE  NE  NE  NE  NE  NE
4´-HO-BDE-17  1.9 × 10–7  2.1 × 10–7  8.8 × 10–6  NE  8.6 × 10–8  6.7 × 10–6  NE  NE
4´-MeO-BDE-17  2.5 × 10–6  NE  NE  NE  8.2 × 10–7  NE  NE  NE
4-HO-BDE-42  2.9 × 10–6  3.6 × 10–6  NE  NE  1.1 × 10–6  NE  NE  NE
4-MeO-BDE-42  NE  NE  NE  NE  1.7 × 10–6  NE  NE  NE
4´-HO-BDE-49  NE  NE  2.3 × 10–6  3.6 × 10–6  1.5 × 10–6  5.5 × 10–6  NE  NE
4´-MeO-BDE-49  NE  NE  4.4 × 10–6  6.1 × 10–6  8.5 × 10–7  6.2 × 10–6  NE  NE
4-HO-BDE-90  NE  NE  NE  NE  NE  NE  8.1 × 10–6  7.3 × 10–6
4-MeO-BDE-90  NE  NE  2.6 × 10–6  7.6 × 10–6  2.5 × 10–6  2.5 × 10–6  NE  NE
NE, no effect (REC20 or RIC20 > 1 × 10–5 M).
aConcentration of the test compound showing 20% of the agonistic activity of 10–9 M E2. bConcentration of the test compound showing 20% of the antagonistic activity of 1 × 10–11 M E2 
via ERα, 1 × 10–10 M E2 via ERβ, 1 × 10–10 M DHT via AR, 3 × 10–8 M via GR, 1 × 10–8 M via TRα, or 1 × 10–8 M via TRβ. Kojima et al.
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Agonistic and antagonistic activities of 
the PBDEs and their metabolites via GR. 
Figure 2C shows the dose–response curves for 
HC obtained from the GR assay. In the GR 
assay, although none of 16 compounds tested 
showed any GR agonistic activity, we found 
that 7 compounds, including three PBDE 
congeners (BDEs 85, 99, and 100), had weak 
GR antagonistic activity (Figure 6). The order 
of relative potencies for GR antagonistic activ-
ity was 4-MeO-BDE-90 > 4´-HO-BDE-49 
> 4´-MeO-BDE-49 > 4´-HO-BDE-17, 
Figure 4. Estrogenic and anti  estrogenic effects of 16 PBDEs and their metabolites in the hERβ transactivation assay using CHO cells transiently transfected with 
an expression plasmid for hERβ as well as a reporter-responsive firefly luciferase plasmid and a constitutively active β-galactosidase expression plasmid. The 
firefly luciferase activity was normalized based on the β-galactosidase activity. (A) Cells were treated with 1 × 10–7 to 1 × 10–5 M of the eight PBDEs and their eight 
metabolites. Values represent mean ± SD of three independent experiments and are presented as the percentage of the response, compared with 100% activity 
defined as the activity achieved with 1 × 10–9 M E2. (B) Cells were treated with 1 × 10–6 to 1 × 10–5 M of the six compounds showing ERβ antagonistic activity, or 
with 1 × 10–9 to 1 × 10–7 M TAM in the presence of 1 × 10–10 M E2. Values mean ± SD of three independent experiments and are presented as the percentage of the 
response, taking the activity achieved with 1 × 10–10 M E2 as 100%. 
*p < 0.05 (ANOVA) compared with 1 × 10–10 M E2 alone. 
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Figure 5. Antiandrogenic effects of 16 PBDEs and metabolites in the hAR transactivation assays using CHO cells transiently transfected with an expression plas-
mid for hAR as well as a reporter-responsive firefly luciferase plasmid and a constitutively active β-galactosidase expression plasmid. Cells were treated with 
1 × 10–7 M to 1 × 10–5 M of 16 PBDEs and metabolites, or with 1 × 10–9 M to 1 × 10–7 M of HF in the presence of 1 × 10–10 M DHT to detect AR antagonistic activity. The 
firefly luciferase activity was normalized based on the β-galactosidase activity. Values represent mean ± SD of three independent experiments and are presented 
as the percentage of the response, taking the activity achieved with 1 × 10–10 M DHT as 100%. 
*p < 0.05 (ANOVA) compared with 1 × 10–10 M DHT alone.
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BDE-85 > BDE-99 > BDE-100 (Table 1). 
From a comparison of RIC20 values, we esti-
mated all the antagonistic activities of these 
compounds to be > 1,000-fold lower than 
that of RU-486, a known GR antagonist 
(RIC20 = 5.7 × 10–9 M).
Agonistic and antagonistic activities of the 
PBDEs and their metabolites via TRα1 and 
TRβ1. Figure 2D shows the dose–response 
curves for T3 obtained from the TRα1/β1 
assays. In these assays, although none of 
16 compounds tested showed any TRα1/β1 
agonistic activity, we found that a higher con-
centration (1 × 10–5 M) of 4-HO-BDE-90 
significantly inhibited both TRα1- and TRβ1-
mediated transcriptional activity induced 
by T3, whereas its corresponding metabolite 
4-MeO-BDE-90 did not (Figure 7). From 
comparisons of RIC20 values for TRα1 and 
TRβ1 (Table 1), we estimated the anti-
thyroid hormone activities of 4-HO-BDE-90 
to be similar to those of TBBPA, previously 
reported to be a TR antagonist by Kitamura 
et al. (2005b).
Discussion
In this study, we characterized the poten-
tial hormone receptor activity of 16 PBDEs 
and their HO and MeO metabolites on the 
basis of highly sensitive reporter gene assays 
using CHO-K1 cells, which we transiently 
transfected with expression vectors for hERα, 
hERβ, hAR, hGR, hTRα1, and hTRβ1, 
along with the appropriate reporter plasmids. 
The results summarized in Table 1 reveal that 
these compounds, excluding BDE-15 and 
BDE-209, exhibited not only ERα/β ago-
nistic and AR antagonistic activities but also 
antagonistic activities via ERα/β, GR, and 
TRα1/β1.
Regarding estrogenicity via ERα of the var-
ious PBDE congeners, two studies were based 
on estrogen response element (ERE)-luciferase 
assay using a human T47D breast cancer 
cell line (ER-CALUX; Legler et al. 1999) for 
estrogenic activity testing. Meerts et al. (2001) 
showed that BDE-28 and BDE-100 from 
among the 17 PBDE congeners tested were 
estrogenic, and Hamers et al. (2006) reported 
that estrogenic responses were found for lower 
brominated diphenyl ethers such as BDEs 
28, 47, and 100, among 19 PBDE congeners 
tested in their study. Of 8 PBDE congeners 
tested in our ERα assay using CHO-K1 cells, 
BDEs 28, 47, and 100 were weakly estro-
genic, whereas BDEs 15, 85, 99, 153, and 209 
showed little activity (Figure 3A). These results 
agree well with those of the studies of Hamers 
et al. (2006) and Meerts et al. (2001). In addi-
tion, we demonstrated that three metabolites 
(4´-HO-BDE-17, 4´-MeO-BDE-17, and 
4-HO-BDE-42) were also estrogenic, with 
4´-HO-BDE-17, in particular, showing the 
most potent estrogenic activity among the 
16 tested compounds (Figure 3A). Recently, 
Mercado-Feliciano and Bigsby (2008) also 
Figure 6. GR antagonistic effects of seven PBDEs and metabolites in the hGR transactivation assays using CHO cells transiently transfected with an expression 
plasmid for hGR as well as a reporter-responsive firefly luciferase plasmid and a constitutively active β-galactosidase expression plasmid. Cells were treated 
with 1 × 10–7 M to 1 × 10–5 M of the seven compounds showing GR antagonistic activity, or with 1 × 10–8 M to 1 × 10–6 M of RU-486 in the presence of 3 × 10–8 M 
HC to detect GR antagonistic activity. We normalized the firefly luciferase activity based on the β-galactosidase activity. Values are percentages of the response, 
taking the activity achieved with 3 × 10–8 M HC as 100%, representing means ± SD of three independent experiments. 
*p < 0.05 (ANOVA) compared with 3 × 10–8 M HC alone.
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Figure 7. TRα1 (A) and TRβ1 (B) antagonistic effects of 4-HO-BDE-90 and 4-MeO-BDE-90 in the hTR transactivation assays using CHO cells transiently transfected 
with an expression plasmid for hTRα1 or hTRβ1 as well as a reporter-responsive firefly luciferase plasmid and a constitutively active β-galactosidase expression 
plasmid. Cells were treated with 1 × 10–7 M to 1 × 10–5 M of 4-HO-BDE-90, 4-MeO-BDE-90 or TBBPA in the presence of 1 × 10–8 M T3 to detect TR antagonistic 
activity. Firefly luciferase activity was normalized based on the β-galactosidase activity. Values represent mean ± SD of three independent experiments and are 
presented as the percentage of the response, taking the activity achieved with 1 × 10–8 M T3 as 100%. 
*p < 0.05 (ANOVA) compared with 1 × 10–8 M T3 alone.
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reported that 4´-HO-BDE-17 showed the 
most potent estrogenic activity among six 
mono-HO-PBDE derivatives from a commer-
cial PBDE mixture (DE-71) tested in a trans-
activation assay using the stable reporter system 
ER-positive BG1Luc4E2 ovarian cancer cells. 
Their results supported those from our study. 
On the other hand, to date, there is no infor-
mation on the estrogenicity of MeO-PBDEs. 
In the present study, we found that 4´-MeO-
BDE-17 has weak estrogenic activity via 
ERα, although its activity was approximately 
15-fold lower than that of 4´-HO-BDE-17. 
This difference indicates that MeO-PBDEs 
are weaker ERα agonists than their corre-
sponding HO-PBDEs, suggesting that the 
hydroxyl group might play an important role 
in the binding affinity to ERα. Furthermore, 
we found that BDE-99, BDE-153, 4´-HO-
BDE-17, 4´-HO-BDE-49, 4´-MeO-BDE-49, 
and 4-MeO-BDE-90 showed dose-dependent 
ERα antagonistic activity in the presence of 1 × 
10–11 M E2 (Figure 3B). Excluding BDE-153, 
which has been reported as an ER antagonist 
(Meerts et al. 2001), we newly identified that 
these five compounds have anti  estrogenic prop-
erties via ERα. Regarding the structure–activity 
relationship of these compounds, the common 
structure of 2,2´,4,4´,5-substituted diphenyl 
ethers may be important in inhibiting ERα-
mediated estrogenic activity, because BDE-99, 
4´-HO-BDE-49, and 4´-MeO-BDE-49 
showed similar ERα antagonistic activity. In 
addition, although 4´-HO-BDE-17 is a very 
potent ERα agonist, it also shows ERα antago-
nistic activity at a high dose (1 × 10–5 M), 
which explains the decrease in its agonistic 
activity shown in Figure 3A. However, 4-HO-
BDE-90 did not induce or inhibit the ERα-
mediated transcriptional activity, suggesting 
that presence of two bromine atoms next to the 
para-HO group may interfere with binding to 
ERα, or the absence of the bromine atoms next 
to the para-HO group (an isolated para-HO 
group) may be important for the induction of 
high estrogenic activity. Taken together, these 
results suggest that several PBDE congeners 
and their HO and MeO analogues might act 
as ERα agonists and/or antagonists, which is 
similar to the results for PCB observed pre-
viously by Connor et al. (1997) and Korach 
et al. (1988).
Although the results we obtained from the 
ERβ assay were similar to those of the ERα 
assay, with 4´-HO-BDE-17 showing the 
strongest estrogenic activity, we found that 
BDE-100 showed antagonistic activity in the 
ERβ assay despite showing agonistic activ-
ity in the ERα assay. This suggests that the 
bromine atom on the 6-position may play an 
important role on the discrepancy between 
ERα- and ERβ-mediated transcriptional activi-
ties. The overall structure of the ERβ-ligand 
binding domain is very similar to that of the 
ERα-ligand binding domain, and most of the 
compounds demonstrate similar binding affini-
ties to and transcriptional activities with ERα 
and ERβ (Kuiper et al. 1997). However, some 
chemicals have been reported to have activi-
ties that vary according to ER subtype. The 
bisphenolic metabolite of methoxychlor, 2,2-
bis-(p-hydroxyphenyl)-1,1,1-trichloroethane 
(HPTE), for example, has been shown to act 
as an ERα agonist and ERβ antagonist in 
human hepatoma (HepG2) cells (Gaido et al. 
2000). We also found that several phthalates 
and HPTE act as an ERα agonist and ERβ 
antagonist in CHO-K1 cells (Takeuchi et al. 
2005). The mechanism under  lying this varia-
tion in activity via ERα and ERβ is thought 
to involve the helix 12 region present in both 
estrogenic receptors, and the agonist orienta-
tion of helix 12 in ERβ has been reported to 
be unstable and thus more likely to be antago-
nistic than that in ERα (Gaido et al. 2000). 
Thus, PBDEs may also be able to stabilize helix 
12 in the agonist orientation for ERα but not 
for ERβ. As a result, we have provided the first 
evidence that BDE-100 has different transcrip-
tional activities via ERα and ERβ.
In vivo and in vitro anti  androgenicity of 
PBDEs have been reported by Stoker et al. 
(2005) and Hamers et al. (2006). Their studies 
indicated that, among principle PBDE conge-
ners, BDE-100 showed potent anti  androgenic 
activity. In the present study, although none 
of the tested compounds showed any andro-
genic activity, 12 PBDEs, including metabo-
lites, possessed AR antagonistic activity, with 
4´-HO-BDE-17 showing the most potent 
anti  androgenic activity of all compounds 
tested, followed by BDE-100 (Figure 5). These 
results suggest that the PBDEs with three to 
five bromine substitutions have anti  androgenic 
activities via AR, and 4´-HO-BDE-17 acts as 
a potent AR antagonist in addition to being a 
potent ERα and ERβ agonist. On the other 
hand, 4-HO-BDE-90 had reduced binding 
ability to AR as well as to ERs compared with 
that of 4-MeO-BDE-90, possibly because of 
the presence of two bromines adjacent to the 
hydroxyl group on the phenyl group. Thus, 
many PBDEs, including their metabolites, 
simultaneously show both ERα/β-agonistic 
and ERα/β- and AR-antagonistic activities. 
We and other researchers have already shown 
that a large number of environmental estro-
gens are also anti  androgenic (Kojima et al. 
2004; Sohoni and Sumpter 1998; Vinggaard 
et al. 1999). The transcriptional activities of 
these active PBDEs via ERα/β and/or AR may 
require the number of bromine substitutions 
and their position on the diphenyl ether struc-
ture. In a previous study (Kojima et al. 2004) 
we demonstrated that the diphenyl ether-type 
herbicides chloronitrofen and chlomethoxyfen 
possess the most potent AR antagonistic activi-
ties (RIC20 = 4.3 × 10–8 M and 6.8 × 10–8 M, 
respectively) along with 4´-HO-BDE-17. These 
results suggest that halogenated compounds 
having a diphenyl ether structure may be 
potentially potent AR antagonists, and thereby 
anti  androgenic PBDEs of greater potency than 
4´-HO-BDE-17 may exist among other PBDE 
isomers not tested in this study.
Glucocorticoids are steroid hormones 
essential for normal growth and develop-
ment, for liver and immune functions, and 
for mediated stress responses. The actions of 
gluco  corticoids are mediated by binding to 
the GR, a member of the nuclear receptor 
superfamily. To our knowledge, no PBDE 
congeners or their metabolites have previ-
ously been reported to possess GR agonistic 
or antagonistic activity. In the present study, 
we provided the first evidence that 7 of the 
16 PBDE compounds tested have similar 
GR antagonistic activity at concentrations of 
10–6 M order. Interestingly, these compounds 
include the penta-BDEs BDE-85, BDE-99, 
and BDE-100, as well as 4´-HO-BDE-49 
and 4´-MeO-BDE-49, which correspond 
structurally to BDE-99. In a recent study, 
Molina-Molina et al. (2006) reported that 
M2 (3´,5´-dichloro-2-hydroxy-2-methyl-
but-3-enanilide), one of the two primary 
metabolites of the dicarboximide fungicide 
vinclozolin, showed GR antagonistic activity. 
However, the structures common to non-
steroidal GR antagonists might be not fully 
clarified because there have been few reports 
on chemicals with known GR activity. Thus, 
although the potencies of the PBDEs and 
their metabolites are low when compared with 
RU-486, a known steroidal GR antagonist, 
their potential for an additive or synergistic 
effect via GR should be taken into consider-
ation in the risk assessment process.
Several studies have reported that 
PBDEs and HO-PBDEs bind competitively 
with human transthyretin (TTR), a trans-
port protein for the thyroid hormones T3 
and thyroxine (T4), thereby hampering the 
transportation of thyroid hormone (Meerts 
et al. 2000; Richardson et al. 2008; Zhou 
et al. 2001, 2002). It is of particular interest 
that the binding activity of 4-HO-BDE-42 
and 4´-HO-BDE-49 for TTR is 1,400-fold 
higher than that of their parent BDE-47 and 
3-fold higher than that of natural ligand T4 
(Hamers et al. 2008). On the other hand, 
few studies have addressed the binding ability 
of PBDEs with TR, except for a competi-
tive binding study using rat TR by Kitamura 
et al. (2008). In the present study, we inves-
tigated hTRα1/β1 agonistic and antagonistic 
activity of 16 PBDEs and metabolites using 
CHO-K1 cell–based reporter gene assays. As 
a result, we demonstrated for the first time 
that only 4-HO-BDE-90 has antagonistic 
activity against both TRα1 and TRβ1, which 
is similar to the results for TBBPA (Kitamura Hormone receptor activity of PBDEs and metabolites
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et al. 2005b). This result supports those from 
Kitamura et al. (2008), who reported that 
4-HO-BDE-90 bound to rat TR. The TR 
antagonists TBBPA and 4-HO-BDE-90 have 
common structures, including a 4-hydroxyl 
group and two bromine substitutions adjacent 
to the hydroxyl group on the phenyl group, 
that are also shared by HO-PCBs as reported 
in some studies (Cheek et al. 1999; Kitamura 
et al. 2005a). This finding may indicate the 
essential structural factors for binding to TR, 
although binding affinities of these com-
pounds might be much lower than those of 
the endogenous ligands T3 and T4.
As discussed above, our study suggests that 
principle PBDE congeners found in human 
tissues and their HO and MeO metabolites 
have multiple endocrine-disrupting effects 
via nuclear hormone receptors. In particu-
lar, the para-HO-PBDEs used in this study 
have been reported to be HO metabo  lites 
found in blood samples from rats and mice 
administrated seven equimolar PBDE conge-
ners (BDEs 47, 99, 100, 153, 154, 183, and 
200) and a commercial penta-PBDE mixture 
DE-71 containing BDEs 47, 99, 153, and 
154, respectively (Malmberg et al. 2005; Qui 
et al. 2007). Therefore, it has been consid-
ered that these metabolites may in fact act as 
endocrine disruptors in humans as well as in 
rodents. Most recently, two reports on PBDE 
metabo  lites identified in human blood sam-
ples have been published. Athanasiadou et al. 
(2008) reported that, of several HO-PBDEs, 
6-HO-BDE-47, 4´-HO-BDE-17, and 
4´-HO-BDE-49 were the dominant phenolic 
metabolites in blood samples from children 
living or working at a municipal waste dis-
posal site in Managua, Nicaragua. On the 
other hand, Qui et al. (2009) reported that 
the metabolite profile in blood samples from 
pregnant women and their newborn babies 
living in the United States was very different 
from the results of Athanasiadou et al. (2008): 
Two metabolites formed without a bromine 
shift (5-HO-BDE-47 and 5´-HO-BDE-99) 
were more abundant, although 4´-HO-
BDE-49 and 4-HO-BDE-42 were detected 
at much lower concentrations in some of the 
20 human blood samples. This also suggests 
that there are differences in the metabolic 
profile of human individuals and between 
humans and rodents because of species dif-
ferences in CYP enzyme expression. Thus, 
further analytical study on PBDE metabo-
lites, including MeO derivatives, in humans is 
required for health risk assessment.
Transactivation assays using CHO-K1 cells 
revealed that PBDEs and their metabolites act 
as an agonist and/or antagonist via ERα/β, 
AR, GR, and TRα/β, suggesting that they 
might have the potential to affect the endo-
crine system. The ligand-dependent activation 
of nuclear receptors requires ligand-dependent 
association of protein cofactors and basal tran-
scription factors, for whose expression levels 
differ from cell to cell (McKenna et al. 1999). 
Furthermore, there is some discrepancy in the 
cellular metabolic ability against chemicals 
between CHO-K1 and other cell lines such as 
hepatocarcinoma cells. Thus, there is a possi-
bility that use of different cells yields different 
results. However, we think that it is important 
to evaluate several receptor activities of chemi-
cals under the same cell conditions using one 
highly sensitive and specific assay method, and 
the reporter gene assays using CHO-K1 cells 
are useful for identifying endocrine disruptors.
Interestingly, the anti  estrogenic and anti-
androgenic properties of PBDE-153 found in 
this study are very similar to those of PCB-153, 
which is known to accumulate in human blood 
(Bonefeld-Jørgensen et al. 2001). These effects 
against ER and AR may reflect structural resem-
blance between PBDE and PCB. Thus, because 
many PBDEs, including those not used in this 
study, are speculated to have nuclear hormone 
receptor activities, we plan to study their effects, 
particularly those of accumulative PBDE 
metabolites such as 6-HO-BDE-47, 5-HO-
BDE-47, and 5´-HO-BDE-99 recently found 
in human blood (Athanasiadou et al. 2008; Qui 
et al. 2009). In addition, another study has indi-
cated that PBDEs are able to induce the expres-
sion of CYP3A11- and CYP2B10-metabolizing 
enzymes by functioning as a ligand of pregnane 
X receptor (PXR), a member of the nuclear 
receptor super  family (Pacyniak et al. 2007). 
These enzymes contribute to the metaboliza-
tion of not only xeno  biotics, such as drugs, but 
also endogenous hormones. Therefore, PBDEs 
may also indirectly disrupt the endocrine 
system by inter  acting with nuclear receptors 
other than hormone receptors, subsequently 
altering metabolizing enzyme activity. Further 
study is required to understand the structure–
activity relationship between PBDEs and 
their metabolites and nuclear hormone recep-
tors, and their pleiotropic effects against other 
nuclear receptors such as PXR and constitutive 
androstane receptor. 
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